Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin

a study on Multiple Myeloma

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
estimated completion
Principal Investigator
by Sandy W Wong
Headshot of Sandy W Wong
Sandy W Wong

Description

Summary

This study will be available to any participant who has received or is currently receiving belantamab mafodotin treatment through either a clinical trial, an access program, or a physician prescription. Participants do not need to be on active treatment. The purpose of this study is to gain a more complete understanding of the pathophysiology of the corneal events seen in some participants with relapsed/refractory multiple myeloma (RRMM) treated with belantamab mafodotin. A superficial corneal epithelial tissue specimen will be obtained by performing impression cytology (IC) or superficial keratectomy (SK) procedure in participants treated with belantamab mafodotin. The procedure will only be performed in one eye, most affected by the corneal epithelial changes. This specimen will undergo pathologic examination and composition analysis. Study duration will be approximately 4 months. Approximately 25 participants will be enrolled in the study.

Official Title

Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin (GSK2857916)

Keywords

Multiple Myeloma, Belantamab mafodotin, Impression cytology, Superficial keratectomy, Relapsed/Refractory multiple myeloma

Eligibility

You can join if…

Open to people ages 18 years and up

  • Male or female, aged 18 years or older (at the time consent is obtained).
  • Capable of providing signed written informed consent, which includes compliance with the requirements and restrictions listed on the consent form.

  • Participants with RRMM who have received or are currently receiving treatment with belantamab mafodotin and diagnosed with microcyst-like epithelial changes (MECs) on slit-lamp examination or confocal microscopy, with or without symptoms, in at least one eye.

    a) If participants only had superficial punctate keratopathy with no evidence of MEC's they are not eligible.

  • If undergoing SK procedure, treating provider has determined there is no excessive risk to the participant.

You CAN'T join if...

  • Any serious and or/unstable medical or psychiatric disorder, or other conditions that could interfere with the participant's safety.
  • Any excess risk of delayed wound healing (For example, diabetes mellitus).
  • Do not meet criteria specified by the study or program through which they would receive belantamab mafodotin.
  • Any participant taking concurrent medication that may affect the cornea (that is. amiodarone, some chloroquines).
  • Any participant with decreased corneal sensation.
  • Eye infections, including infectious keratopathy, stye, blepharitis, and conjunctivitis.
  • An active uveitis including anterior, posterior, or panuveitis in either eye.
  • Permanent legal blindness in the fellow (non-study) eye.

Locations

  • GSK Investigational Site accepting new patients
    San Francisco California 94143 United States
  • GSK Investigational Site accepting new patients
    Westwood Kansas 66205 United States

Lead Scientist at UCSF

  • Sandy W Wong
    Assistant Professor, Medicine, School of Medicine. Authored (or co-authored) 98 research publications. Research interests: amyloidosis · plasma cell dyscrasias · multiple myeloma · MGUS · SMM

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
GlaxoSmithKline
ID
NCT04549363
Phase
Phase 3 Multiple Myeloma Research Study
Study Type
Interventional
Participants
Expecting 25 study participants
Last Updated
Contact us about this trial